Synthetic studies on the flavone derivatives. XIII. Synthesis of flavones with tetramethoxyl groups in ring B.
作者:MUNEKAZU IINUMA、TOSHIYUKI TANAKA、SHIN MATSUURA
DOI:10.1248/cpb.32.3354
日期:——
2', 3', 4', 5, 5', 6, 7, 8-Octamethoxy-(Ia) and 2', 3', 4', 5, 5', 6, 7-heptamethoxyflavone (IIa) and their position isomers substituted with tetramethoxyl groups in ring B were synthesized to confirm the structures of agehoustin A and agehoustin B isolated from Ageratum houstonianum. The characteristics of the synthesized flavones were investigated by spectroscopic methods.
Two polymethoxyflavones from Ageratum houstonianum
作者:L. Quijano、J.S. Calderón、F. Gómez、T. Ríos
DOI:10.1016/0031-9422(80)85078-3
日期:1980.1
Abstract Besides agecorynin C, eupalestin and lucidin dimethyl ether, two new highly oxygenated flavones were isolated fromAgeratumhoustonianum . Their structures were established by spectroscopic and degradative evidence as 5, 6, 7, 8, 2′, 3′, 4′, 5′-octamethoxyflavone and 5, 6, 7, 2′, 3′, 4′, 5′-heptamethoxyflavone.
BHARDWAJ, D. K.;CHAND, GYAN;JAIN, A.;SRIVASTAVA, NAGESH;SHARMA, A. K., INDIAN J. CHEM., 25,(1986) N 11, 1163-1164
作者:BHARDWAJ, D. K.、CHAND, GYAN、JAIN, A.、SRIVASTAVA, NAGESH、SHARMA, A. K.
DOI:——
日期:——
[EN] COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE TROUBLES NEURODÉGÉNÉRATIFS ET MÉTABOLIQUES
申请人:SCRIPPS RESEARCH INST
公开号:WO2020232255A1
公开(公告)日:2020-11-19
Compounds described herein may be used for the treatment of neurodegenerative diseases linked to protein misfolding, including prion diseases, Alzheimers' disease, Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), and also other neurodegenerative, degenerative, metabolic and ischemic conditions. Indeed, NAD metabolism impairment is also a critical feature in brain ischemia/reperfusion injury, Wallerian degeneration, kidney failure, multiple sclerosis, aging, and metabolic disorders such as diabetes mellitus. Therapies that elevate or stabilize NAD levels may thus have broad potential for treating many severely debilitating neurological and metabolic conditions. Evidence is provided herein with compounds from 8 lead series for NAD restoring properties and for therapeutic efficacy in cellular and/or animal models of prion disease, PD and ALS.